RxDoctor Payments Data

Erika Paula Pizarro, MD

Psychiatry · San Francisco, CANPI 1619238417

Payments from drug & device makers

$5,485in general payments, 2019–2025

Across 225 payments — averaging $24.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Axsome Therapeutics, Inc.$726
  • Takeda Pharmaceuticals U.S.A., Inc.$597
  • Alkermes, Inc.$474
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$432
  • Noven Therapeutics, LLC$352
  • plus $1K from 10 others

What the payments were for

  • Food & beverage$5,485100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,485 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$8,000
Medicare patients
11
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl21$39,388
TrintellixVortioxetine Hydrobromide12$5,549
Lisdexamfetamine Dimesylate12$4,246
Duloxetine Hcl40$1,382
Fluvoxamine Maleate12$754
Bupropion XlBupropion Hcl35$734
Quetiapine Fumarate44$552
Gabapentin22$550
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine21$494
Fluoxetine Hcl28$437
Trazodone Hcl34$390
Escitalopram Oxalate18$283
Sertraline Hcl23$254
Lamotrigine18$192
Clonazepam52$188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,609$39,38821 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$597$5,54912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.

Other psychiatry in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →